Performance status in patients with hepatocellular carcinoma: Determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system

Hepatology

Volumn 57, Issue 1, 2013, Pages 112-119

  Hsu, Chia Yang ^a,b   Lee, Yun Hsuan ^a,b   Hsia, Cheng Yuan ^a,b   Huang, Yi Hsiang ^a,b   Su, Chien Wei ^a,b   Lin, Han Chieh ^a,b   Lee, Rheun Chuan ^a,b   Chiou, Yi You ^a,b   Lee, Fa Yauh ^a,b   Huo, Teh Ia ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BILIRUBIN;

ADULT; AGE DISTRIBUTION; ALCOHOLISM; ARTICLE; BARCELONA CLINIC LIVER CANCER SYSTEM; BILIRUBIN BLOOD LEVEL; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT TOOL; DIABETES MELLITUS; FEMALE; GLOMERULUS FILTRATION RATE; HEPATITIS B; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; HYPONATREMIA; INTERMETHOD COMPARISON; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER FUNCTION; LONG TERM SURVIVAL; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRIORITY JOURNAL; PROTHROMBIN TIME; TUMOR VOLUME;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TAIWAN;

EID: 84872153048     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.25950     Document Type: Article

References (34)

1. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-474.
2. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817-823.
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. HEPATOLOGY 2005; 42: 1208-1236.
4. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
5. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. HEPATOLOGY 2005; 41: 707-716.
6. Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Loong CC, et al. A new prognostic model for hepatocellular carcinoma based on total tumor volume: the Taipei Integrated Scoring System. J Hepatol 2010; 53: 108-117.
7. Hsu CY, Huang YH, Su CW, Lin HC, Lee PC, Loong CC, et al. Selecting an optimal staging system for Hepatocellular carcinoma: Comparison of 5 currently used prognostic models. Cancer 2010; 116: 3006-3014.
8. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; 54: 411-418.
9. Guglielmi A, Ruzzenente A, Pachera S, Valdegamberi A, Sandri M, D'Onofrio M, et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol 2008; 103: 597-604.
10. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
11. Grant BF, Dufour MC, Harford TC. Epidemiology of alcoholic liver disease. Semin Liver Dis 1988; 8: 12-25.
12. Gonwa TA, Jennings L, Mai ML, Stark PC, Levey AS, Klintmalm GB. Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 2004; 10: 301-309.
13. Lamb EJ, Tomson CR, Roderick PJ. Estimating kidney function in adults using formulae. Ann Clin Biochem 2005; 42: 321-345.
14. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-699.
15. Huo TI, Lin HC, Huang YH, Wu JC, Chiang JH, Lee PC, et al. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer 2006; 107: 141-148.
16. Huo TI, Huang YH, Lin HC, Wu JC, Chiang JH, Lee PC, et al. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol 2006; 101: 975-982.
17. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat Med 1997; 16: 965-980.
18. Feinstein AR. Clinical biostatistics. XVI. The process of prognostic stratification. Clin Pharmacol Ther 1972; 13: 609-624.
19. Chen YM, Shih JF, Fan WC, Wu CH, Chou KT, Tsai CM, et al. Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status. J Chin Med Assoc 2011; 74: 209-214.
20. Penel N, Glabbeke MV, Mathoulin-Pelissier S, Judson I, Sleijfer S, Bui B, et al. Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study. Br J Cancer 2011; 104: 1544-1550.
21. Hsu CY, Huang YH, Hsia CY, Su CW, Lin HC, Lee RC, et al. Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact and staging strategy. Hepatol Int 2012 [Epub ahead of print].
22. Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Chiou YY, et al. Differential prognostic impact of renal insufficiency on patients with hepatocellular carcinoma: a propensity score analysis and staging strategy. J Gastroenterol Hepatol 2012; 27: 690-699.
23. Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130: 1652-1660.
24. Huang HC, Lee FY, Huo TI. Major adverse events, pretransplant assessment and outcome prediction. J Gastroenterol Hepatol 2009; 24: 1716-1724.
25. Huo TI, Hsu CY, Huang YH, Su CW, Lin HC, Lee RC, et al. Prognostic prediction across a gradient of total tumor volume in patients with hepatocellular carcinoma undergoing locoregional therapy. BMC Gastroenterol 2010; 10: 146.
26. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000; 31: 302-308.
27. Poon RT, Fan ST, Lo CM, Liu CL, Ngan H, Ng IO, et al. Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management. Am J Gastroenterol 1999; 94: 2460-2466.
28. Mirici-Cappa F, Gramenzi A, Santi V, Zambruni A, Di Micoli A, Frigerio M, et al. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut 2010; 59: 387-396.
29. Huo TI, Hsu CY, Huang YH, Hsia CY, Lin HC, Lee PC, et al. Diabetes mellitus as an independent prognostic predictor and its association with renal dysfunction in patients with hepatocellular carcinoma. Liver Int 2010; 30: 198-207.
30. Lee YH, Hsu CY, Hsia CY, Huang YH, Su CW, Chiou YY, et al. Alcoholism worsens the survival of patients with hepatitis B virus and C virus-related hepatocellular carcinoma. Hepatol Int 2012 [Epub ahead of print].
31. Hsu CY, Hsia CY, Huang YH, Su CW, Lin HC, Pai JT, et al. Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: A propensity score analysis. Ann Surg Oncol 2012; 19: 842-849.
32. Hsu CY, Huang YH, Chiou YY, Su CW, Lin HC, Lee RC, et al. Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Transpl 2011; 17: 556-566.
33. Tsai YJ, Hsu CY, Huang YH, Su CW, Lin HC, Lee RC, et al. Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma. Hepatol Int 2011; 5: 975-984.
34. Yang JD, Kim WR, Park KW, Chaiteerakij R, Kim B, Sanderson SO, et al. Model to estimate survival in ambulatory patients with hepatocellular carcinoma. HEPATOLOGY 2012 [Epub ahead of print].